AC
BTAI icon

Ascend Capital’s BioXcel Therapeutics BTAI Stock Holding History

Ascend Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,531
Closed -$2.05M – 184
2018
Q1 		$2.05M Buy
+12,531
New +$2.09M 0.08% 162

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Prudence Asset Management Hong Kong $3.65M AUM 36.79% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DIM
DC Investments Management Mclean, Virginia $261M AUM 20.71% 1-Year Est. Return

Ascend Capital's BTAI Position: Q2 2018 in Review

Ascend Capital sold out of BioXcel Therapeutics (BTAI) in Q2 2018, closing a stake of 12,531 shares — an estimated $2.05M sold.

Ascend Capital first reported a position in BTAI in Q1 2018 and held it in 1 quarter. The position peaked at $2.05M in Q1 2018. 20 funds tracked by Wall St. Rank hold BTAI as of Q2 2018.

  • Ascend Capital reported no remaining BioXcel Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 12,531 BioXcel Therapeutics shares in Q2 2018, an estimated $2.05M.
  • Ascend Capital first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 1 quarter.
  • Ascend Capital's BioXcel Therapeutics position peaked at $2.05M in Q1 2018.
  • 20 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.